Press releases

FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma

Regulatory

February 26, 2021

STOCKHOLM — February 26, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today a...

Read more

YEAR-END REPORT 2020

Regulatory

February 18, 2021

Summary Q4

Read more